Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study

Background: The development of newer agents, including anti-CD38 monoclonal antibodies (mAbs), has significantly improved overall survival (OS) in patients with relapsed or refractory multiple myeloma (RRMM). However, the treatment of older patients with RRMM who are transplant-ineligible remains ch...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Satoshi Yamasaki, Michitoshi Hashiguchi, Nao Yoshida-Sakai, Hiroto Jojima, Koichi Osaki, Takashi Okamura, Yutaka Imamura
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2024-11-01
سلاسل:	Hematology Reports
الموضوعات:	older patients multiple myeloma relapsed or refractory daratumumab isatuximab propensity score matching analysis
الوصول للمادة أونلاين:	https://www.mdpi.com/2038-8330/16/4/68
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!